Tokyo, May 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061423) titled 'Long-term outcomes of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors' on April 30.
Study Type:
Observational
Primary Sponsor:
Institute - Okayama university
Condition:
Condition - Pancreatic neuroendocrine tumors
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a minimally invasive treatment option for small, low-grade pancreatic neuroendocrine neoplasms (PNENs). While a multicenter prospective study is currently evaluating its short-term efficacy and safety, data on long-term outcomes remain limited. This study aims to prospectively assess the long-term outcomes following EUS-RFA as an ancillary study, focusing on local recurrence, distant metastasis, and long-term effects on pancreatic endocrine and exocrine function.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who participated in the multicenter prospective study titled (Evaluation of the efficacy and safety of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms).
Patients from whom written informed consent for participation in this study can be obtained based on their own free will.
Key exclusion criteria - none
Target Size - 35
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 04 Month 30 Day
Anticipated trial start date - 2027 Year 02 Month 01 Day
Last follow-up date - 2035 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070284
Disclaimer: Curated by HT Syndication.
